盐酸托泊替康(Topotecan Hydrochloride) - 药物靶点：TOP1_在研适应症：实体瘤，卵巢上皮癌，小细胞肺癌复发_专利_临床

概要

基本信息

药物类型

小分子化药

别名

9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin、Nogitecan hydrochloride (JAN)、topotecan

+ [21]

靶点

TOP1

作用机制

TOP1抑制剂(DNA拓扑异构酶I抑制剂)

治疗领域

肿瘤内分泌与代谢疾病呼吸系统疾病+ [4]

在研适应症

实体瘤卵巢上皮癌小细胞肺癌复发+ [16]

非在研适应症

习惯性流产急性红细胞白血病急性白血病+ [93]

原研机构

GSK Plc

在研机构

Pfizer Inc.

Hospira, Inc.Pfizer Ltd.

+ [9]

非在研机构

GSK Plc上海交通大学医学院附属新华医院Teva Pharmaceuticals Europe BV

+ [12]

最高研发阶段批准上市

首次获批日期

美国 (1996-05-28),

卵巢癌小细胞肺癌宫颈癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

结构

分子式C23H24ClN3O5

InChIKeyDGHHQBMTXTWTJV-BQAIUKQQSA-N

CAS号119413-54-6

关联

370

项与盐酸托泊替康相关的临床试验

NCT06425419 / Not yet recruiting临床1期IIT

The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from an open globe injury, and compare the outcomes to those who do no receive intravitreal topotecan. The main objectives it aims to achieve are:
to study the safety profile of intravitreal topotecan in the treatment of PVR
to evaluate the efficacy of intravitreal topotecan in treating PVR.
Post-consent, participants will:
undergo vitrectomy (with or without scleral buckle) as part of standard treatment for retinal detachment.
receive intravitreal topotecan at the time of surgery, post-operative day 7 and post-operative day 28 (if randomized to receive the medication)
come in at post-operative day 1, 7, 28, 56, 84, 126 and 168 to undergo a complete ophthalmic exam along with a fundus photography and optical coherence tomography of the macula, have their intraocular pressure and visual acuity measured and their adverse events monitored, if any.
Researchers will compare participants who receive intravitreal topotecan for PVR to those who do not to see if there is a significant variability in recurrence of retinal detachment, rate of retinal reattachment and PVR grade 6 months after surgery.

开始日期2024-07-01

申办/合作机构

Massachusetts Eye & Ear Infirmary, Inc.

NCT06172296 / Recruiting临床3期IIT

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

开始日期2024-04-19

申办/合作机构

National Cancer Institute

NCT05990738 / Recruiting临床1期

DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With Topotecan for the Treatment of Patients With Small Cell Lung Cancer

This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive topotecan treatment.
The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets).
Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.

开始日期2024-01-15

申办/合作机构

Boehringer Ingelheim GmbH

100 项与盐酸托泊替康相关的临床结果

登录后查看更多信息

100 项与盐酸托泊替康相关的转化医学

登录后查看更多信息

100 项与盐酸托泊替康相关的专利（医药）

登录后查看更多信息

3,231

项与盐酸托泊替康相关的文献（医药）

2024-12-01·Molecular biology reports

Synergistic effect of a nonsteroidal anti-inflammatory drug in combination with topotecan on small cell lung cancer cells

Article

作者: Ozkan, Asuman Deveci ; Kanli, Aylin ; Yanar, Sevinc ; Eskiler, Gamze Guney ; Bal Albayrak, Merve Gulsen ; Kasap, Murat

BACKGROUND:

The topoisomerase I inhibitor topotecan (TPT) is used in the treatment of recurrent small cell lung cancer (SCLC). However, the drug has a limited success rate and causes distress to patients due to its side effects, such as hematologic toxicities, including anemia and thrombocytopenia. Due to these pharmacokinetic limitations and undesirable side effects of chemotherapeutic drugs, the development of combination therapies has gained popularity in SCLC. Meclofenamic acid (MA), a nonsteroidal anti-inflammatory drug, has demonstrated anticancer effects on various types of cancers through different mechanisms. This study aims to investigate the potential synergistic effects of MA and TPT on the small cell lung cancer cell line DMS114.

METHODS AND RESULTS:

To assess the cytotoxic and apoptotic effects of the combined treatment of MA and TPT, trypan blue exclusion assay, Annexin V, acridine orange/propidium iodide staining, western blot, and cell cycle analysis were conducted. The results demonstrated that the combination of MA and TPT elicited synergistic effects by enhancing toxicity in DMS114 cells (P < 0.01) without causing toxicity in healthy epithelial lung cells MRC5. The strongest synergistic effect was observed when the cells were treated with 60 µM MA and 10 nM TPT for 48 h (CI = 0,751; DRI = 10,871).

CONCLUSION:

This study, for the first time, furnishes compelling evidence that MA and TPT synergistically reduce cellular proliferation and induce apoptosis in SCLC cells. Combinations of these drugs holds promise as a potential therapeutic strategy to improve efficacy and reduce the side effects associated with TPT.

2024-04-01·Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma

Article

作者: Bretana, Maria E ; Zhou, Brenda ; Rusakevich, Alexander M ; Dannenbaum, Mark J ; Schefler, Amy C ; Nahhas, Michael I

PURPOSE:

To identify the specific clinical and angiographic variables that determine the success of intra-arterial chemotherapy (IAC) in a patient with retinoblastoma.

METHODS:

Medical records from patients undergoing intra-arterial chemotherapy for the treatment of retinoblastoma between January 2015 and June 2020 within a large academic ocular oncology practice were retrospectively reviewed. Demographics were recorded together with clinical, ocular, and angiographic variables such as the diameter of the ophthalmic artery (OA), angle of ophthalmic artery takeoff, and branching pattern of ophthalmic vasculature.

RESULTS:

Forty-four eyes from 33 patients with retinoblastoma treated with IAC were identified. Over the total 32 mean months of follow-up, these patients received 144 total catheterizations and a mean of 3.2 IAC cycles for each eye. The number of IAC cycles and the chemotherapeutic agent used did not vary significantly with worsening International Classification of Retinoblastoma (ICRB) groups (P > 0.1). Cumulative dose did not vary with the ICRB group for eyes treated with melphalan, topotecan, or carboplatin (P > 0.1). A higher ICRB group was associated with a smaller mean ophthalmic artery diameter across all procedures (P = 0.016), and femoral artery diameter did not vary significantly between ICRB groups (P = 0.906). A higher cumulative dose of IAC was significantly associated with a smaller takeoff angle of the OA (melphalan, P = 0.011; topotecan, P = 0.009; carboplatin, P = 0.031) in patients who underwent successful IAC procedures. Ophthalmic artery diameter and femoral artery diameter did not have a significant association (P > 0.1) with higher IAC doses in successful IACs. Cumulative IAC dose was not significantly associated with ophthalmic vasculature branching pattern, presence of choroidal blush, temporary OA vasospasm reported during the procedure, and OA occlusion upon microcatheter placement.

CONCLUSION:

In this study, neurosurgical angioanatomy appeared to influence the cumulative dose of chemotherapy needed during IAC for retinoblastoma. In the future, these anatomic variables may be used to guide the frequency of monitoring, dosing, and estimation of recurrence risk.

2024-03-01·American journal of ophthalmology case reports

Pushing the limit: Globe salvage of Group D retinoblastoma with severe vitreous seeding with intra-arterial chemotherapy and 15 cycles of intravitreal chemotherapy

作者: Rabiee, Roxanna ; Greig, Eugenia C ; Afshar, Armin R

Purpose:

To report the successful treatment of persistent retinoblastoma vitreous seeding with 6 cycles of intra-arterial chemotherapy and 15 cycles of intravitreal chemotherapy injections.

Observations:

A three-year-old female presented to the ocular oncology clinic with Group D retinoblastoma with severe vitreous seeding. The patient received 3 cycles of intra-arterial chemotherapy (melphalan, topotecan, and carboplatin) and 15 cycles of intravitreal chemotherapy (melphalan and combined melphalan/topotecan). Complete tumor regression and resolution of vitreous seeding was achieved. The best corrected visual acuity in the affected eye was 20/50.

Conclusions and Importance:

Intravitreal chemotherapy for retinoblastoma vitreous seeding is often restricted to 8 treatment cycles. Patients who do not respond after 8 cycles face salvage therapy with radiation or enucleation. This is a case in which prolonged intravitreal chemotherapy delivery was well tolerated and resulted in sustained tumor remission, with useful visual acuity in the treated eye.

191

项与盐酸托泊替康相关的新闻（医药）

2024-06-28

·drugs

NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians

FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National Comprehensive Cancer Network survey. Following data published one year ago and six months ago illustrating shortages of crucial cancer drugs, the National Comprehensive Cancer Network published new results from its most recent survey on cancer drug shortages in the United States. According to the survey, 89 percent of the 28 cancer centers surveyed reported that cancer drugs are in short supply, most often vinblastine (57 percent), etoposide (46 percent), and topotecan (43 percent). Eleven and 7 percent of centers reported that carboplatin and cisplatin, respectively, were in short supply. More than half of the centers surveyed (56 percent) reported being able to treat all patients according to the intended dose and schedule by using mitigation strategies, with waste management strategies and limiting use of current stock (80 and 53 percent, respectively) the most common mitigation strategies implemented. Drug shortages impacted clinical trials at 43 percent of the centers surveyed, most often by greater administrative burden and reduction in enrollments (83 and 58 percent, respectively). "The current situation underscores the need for sustainable, long-term solutions that ensure a stable supply of high-quality cancer medications," Alyssa Schatz, M.S.W., from the National Comprehensive Cancer Network, said in a statement. "The federal government has a key role to play in addressing this issue. Establishing economic incentives, such as tax breaks or manufacturing grants for generic drugmakers, will help support a robust and resilient supply chain -- ultimately safeguarding care for people with cancer across the country." Survey Results Press Release Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-06-26

·PRNewswire

New Survey from NCCN Finds Cancer Drug Shortage Management Remains a Moving Target, Impacting Clinical Trials

Specific carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages. PLYMOUTH MEETING, Pa., June 26, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers—is publishing new results for its latest survey on cancer drug shortages in the United States. This follows data published one year ago, and six months ago, illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial chemotherapy carboplatin at its peak. In June 2023, 70% of centers surveyed were also lacking adequate supply for cisplatin. In the latest survey, only 11% of surveyed centers reported a shortage of carboplatin and 7% for cisplatin; but new concerns have emerged. Continue Reading "Critical drug shortages were not a new problem last year and they continue to be a problem now," explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The dual carboplatin and cisplatin shortage was particularly severe, and we were able to help sound the alarm during its peak. Despite a renewed attention to drug shortages over the past year, 89% of the responding centers in the latest survey are still reporting shortages of various important anti-cancer agents and supportive care medications. Most of them are still managing shortages for more than one type of medication right now. These shortages not only put a burden on patients, caregivers, and providers, but they could also delay vital clinical trials and slow the pace of progress for new cancer therapies." 89% of responding centers are still reporting shortages of important anti-cancer agents and supportive care medications. Post this According to the latest survey results—fielded May 28 through June 11, 2024—of the 28 responding centers, 57% reported a shortage of vinblastine, 46% for etoposide, and 43% for topotecan. Some level of shortage was found for many other chemotherapies and supportive care medications, including dacarbazine, 5-fluorouracil, methotrexate, and others. Many of these drugs form the backbones of effective multi-agent regimens across both curative and palliative treatment settings. The ongoing drug shortages were also found to affect clinical trials at 43% of centers by impacting budgeting, enrollment, and raising administrative burden. 27% reported treatment delays due to shortage-related changes that required additional prior authorization. The responding centers continue to mitigate the impact of shortages through a combination of strategies, including waste reduction management plus adjusted timing and dosage within evidence-based ranges. "The current situation underscores the need for sustainable, long-term solutions that ensure a stable supply of high-quality cancer medications," said Alyssa Schatz, MSW, Senior Director of Policy & Advocacy, NCCN. "The federal government has a key role to play in addressing this issue. Establishing economic incentives, such as tax breaks or manufacturing grants for generic drugmakers, will help support a robust and resilient supply chain—ultimately safeguarding care for people with cancer across the country." Respondents noted concerns about how the current marketplace incentivizes unsustainable practices, with 75% stating they would like to see economic incentives put in place to encourage the high-quality manufacturing of medications, especially generic versions that are often in short supply. 64% felt there was a need for a broader buffer stock payment. The same percentage would like to see more information made available on user experience for various suppliers. The NCCN Policy and Advocacy team has been involved with national efforts, working with federal regulators, agencies, and lawmakers to implement long-term solutions to drug shortages. Learn more and view past and present survey results by visiting NCCN.org/drug-shortages. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN ®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information. Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network

2024-06-03

·医药观澜

先声再明公布抗VEGF抗体注册3期临床数据丨ASCO口头报告

▎药明康德内容团队报道6月2日，先声药业集团旗下抗肿瘤创新药公司先声再明宣布，注射用苏维西塔单抗针对铂耐药卵巢癌的注册3期临床研究（SCORES）最新数据亮相2024美国临床肿瘤学（ASCO）年会最新突破摘要（Late-breaking Abstract，LBA）口头报告。苏维西塔单抗（suvemcitug）是新一代重组人源化抗血管内皮生长因子（VEGF）兔源单克隆抗体。2024年3月，该产品的新药上市申请获得中国NMPA受理，拟联合化疗用于含铂化疗治疗失败的复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。SCORES研究是一项多中心、随机、双盲、安慰剂对照的中国3期临床试验，旨在评估苏维西塔单抗联合研究者选择的化疗（紫杉醇、多柔比星脂质体或拓扑替康）对比安慰剂联合化疗治疗铂耐药复发性卵巢癌的疗效和安全性。2021年6月至2023年6月期间，SCORES研究于中国55家研究中心纳入421例含铂化疗方案治疗失败的复发性上皮卵巢癌、输卵管癌和原发性腹膜癌患者。2024年1月3日，研究达成主要研究终点阳性结果，盲态独立评审委员会（BIRC）评估的苏维西塔单抗组中位无进展生存期（PFS）相比对照组显著延长。本次公布SCORES研究数据表明：经BIRC评估，在全分析集人群（即意向性治疗人群ITT）中，苏维西塔组对比安慰剂组显著延长了无进展生存期，中位PFS 5.49个月 vs. 2.73个月。在所有预先设定的亚组（年龄、ECOG评分、是否存在腹水、基线靶病灶直径和、既往治疗线数、无铂间期、既往接受系统治疗种类数、是否接受过抗血管生成治疗、是否铂难治、研究者选择联用的化疗方案）中，疗效分析均呈现阳性结果，PFS均显著获益。本研究入组的421例受试者中，既往接受VEGF通路治疗的受试者占比50.1%，既往接受PARP抑制剂治疗的受试者占比48.9%，与当下临床实践中的前线治疗分布特征相符，研究结果提示在包括既往使用过VEGF和/或PARP抑制剂的人群中，苏维西塔单抗联合化疗均可显著延长患者PFS。截至主要终点分析日期，关键次要终点总生存期（OS）尚未成熟，中位随访时间分别为14.36个月和14.26个月，中位OS为苏维西塔单抗组16.07个月 vs. 14.88个月，苏维西塔单抗组较对照组呈现出OS获益趋势。其他次要疗效终点中，研究者评估的中位PFS为苏维西塔单抗组5.39个月vs.安慰剂组2.46个月，BIRC评估的ORR为26.0% vs. 12.1%，研究者评估的ORR为23.1% vs. 8.6%，BIRC和研究者评估的DCR和DOR也呈现出一致的获益。苏维西塔单抗联用化疗总体安全性良好，对比同机制药物无新的安全性信号。参考资料：[1苏维西塔单抗注册Ⅲ期临床研究亮相2024 ASCO Late-breaking口头报告. Retrieved June 2, 2024, from https://mp.weixin.qq.com/s/0yEaVpmEz5aMckKG_CCFFw本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床结果临床3期ASCO会议申请上市

100 项与盐酸托泊替康相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02168	盐酸托泊替康	L01XX17	DB01030

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
实体瘤	日本	Nippon Kayaku Co., Ltd.	2013-11-20
卵巢上皮癌	欧盟	Teva Pharmaceuticals Europe BV	2009-09-21
卵巢上皮癌	冰岛	Teva Pharmaceuticals Europe BV	2009-09-21
卵巢上皮癌	列支敦士登	Teva Pharmaceuticals Europe BV	2009-09-21
卵巢上皮癌	挪威	Teva Pharmaceuticals Europe BV	2009-09-21
小细胞肺癌复发	欧盟	-	1996-11-12
小细胞肺癌复发	冰岛	-	1996-11-12
小细胞肺癌复发	列支敦士登	-	1996-11-12
小细胞肺癌复发	挪威	-	1996-11-12
卵巢癌	美国	Sandoz, Inc.	1996-05-28
小细胞肺癌	美国	Sandoz, Inc.	1996-05-28
宫颈癌	美国	Sandoz, Inc.	1996-05-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尤文肉瘤	临床3期	美国	National Cancer Institute	2010-11-22
尤文肉瘤	临床3期	澳大利亚	National Cancer Institute	2010-11-22
尤文肉瘤	临床3期	加拿大	National Cancer Institute	2010-11-22
尤文肉瘤	临床3期	新西兰	National Cancer Institute	2010-11-22
尤文肉瘤	临床3期	波多黎各	National Cancer Institute	2010-11-22
尤文肉瘤	临床3期	沙特阿拉伯	National Cancer Institute	2010-11-22
外周性原始神经外胚层肿瘤	临床3期	美国	National Cancer Institute	2010-11-22
外周性原始神经外胚层肿瘤	临床3期	澳大利亚	National Cancer Institute	2010-11-22
外周性原始神经外胚层肿瘤	临床3期	加拿大	National Cancer Institute	2010-11-22
外周性原始神经外胚层肿瘤	临床3期	新西兰	National Cancer Institute	2010-11-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02308527 (ITCC-SIOPEN BEACON-Neuroblastoma, Pubmed)	临床2期	难治性神经母细胞瘤	160	Temozolomide	選憲憲顧鬱糧獵蓋鑰憲(鏇鑰積構觸顧網鑰糧壓) = 壓鑰餘淵糧齋遞鹽膚壓鏇膚選網範艱鹽醖積夢 (艱膚齋範廠壓鹽廠網繭, 10 ~ 28)	积极	2024-01-08
				Irinotecan-temozolomide	選憲憲顧鬱糧獵蓋鑰憲(鏇鑰積構觸顧網鑰糧壓) = 遞簾襯鏇繭蓋鹽窪憲夢鏇膚選網範艱鹽醖積夢 (艱膚齋範廠壓鹽廠網繭, 17 ~ 37)
ESMO2023	N/A	小细胞肺癌二线	-	Lurbinectedin	淵蓋鏇艱醖範願鏇鏇糧(顧遞壓衊築窪壓鹹築廠) = 鏇繭襯簾衊襯夢積獵艱築鑰積觸壓壓艱蓋膚蓋 (鏇艱顧糧簾網膚餘繭獵 )	-	2023-10-21
				Topotecan with or without trilaciclib	淵蓋鏇艱醖範願鏇鏇糧(顧遞壓衊築窪壓鹹築廠) = 獵醖鹹醖廠獵膚窪衊鹹築鑰積觸壓壓艱蓋膚蓋 (鏇艱顧糧簾網膚餘繭獵 )
ARVO2023	N/A	视网膜母细胞瘤	3	topotecan	窪糧繭構艱願蓋衊積廠(膚襯構願鑰觸鏇簾範製) = 願積鹹餘壓構顧醖餘壓鹽壓廠壓鏇積鬱鏇構淵 (積襯顧鬱壓壓鹽顧衊鏇 ) 更多	-	2023-04-23
				topotecan	窪糧繭構艱願蓋衊積廠(糧遞蓋憲選製衊網醖壓) = 醖膚鹽糧觸鏇製選衊蓋繭蓋糧製窪艱鹹獵淵鑰 (願壓願選窪範窪簾獵構 ) 更多
NCT01600573 (TOPAZ, Pubmed)	临床1/2期	复发性铂耐药性卵巢癌	-	Pazopanib	蓋鬱範繭壓遞鹽糧窪夢(夢鹹鑰壓襯襯襯淵夢艱) = 選夢觸憲夢鑰選憲範鏇壓願醖餘醖壓鏇鏇願衊 (範襯艱積襯積鹹鏇糧觸 )	积极	2023-03-31
NCT00803062 (Gynecologic Oncology Group protocol 240, Pubmed)	临床3期	晚期宫颈癌一线	452	paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2	製憲糧衊艱顧選襯糧糧(鬱夢積觸憲鹽製膚獵製) = 繭鬱繭觸選淵願蓋窪廠製遞蓋築醖襯艱鹽餘憲 (憲選構鹽鑰壓簾醖齋鬱 )	不佳	2023-03-08
				cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2	製憲糧衊艱顧選襯糧糧(鬱夢積觸憲鹽製膚獵製) = 膚淵簾積選壓襯遞獵蓋製遞蓋築醖襯艱鹽餘憲 (憲選構鹽鑰壓簾醖齋鬱 )
NeCTuR (IGCS2022)	N/A	复发性宫颈癌二线	-	Topotecan, paclitaxel, and bevacizumab (TPB)	繭糧膚繭遞餘製餘觸餘(網壓觸觸網築顧醖觸衊) = 淵築鑰憲願鹹鏇餘範窪壓簾構顧繭鹽築蓋網壓 (製積選構範網鬱餘蓋繭 ) 更多	积极	2022-12-04
				Chemotherapy without TPB	繭糧膚繭遞餘製餘觸餘(網壓觸觸網築顧醖觸衊) = 顧壓壓網襯艱網觸鏇膚壓簾構顧繭鹽築蓋網壓 (製積選構範網鬱餘蓋繭 ) 更多
NCT04768296 (DDRiver SCLC 250, ESMO2022) 人工标引	临床2期	小细胞肺癌复发 \| 小细胞癌	6	Berzosertib 105 mg/m2+Topotecan 1.25 mg/m2 (solid tumours)	淵構壓鏇鏇憲獵顧糧鑰(蓋壓鹹淵構艱積醖鹹遞) = 鑰艱鏇襯顧夢憲觸獵觸鏇網網膚衊襯製繭範鹽 (糧鏇網鏇窪繭網衊窪鑰 ) 更多	积极	2022-09-10
				Berzosertib 210 mg/m2+Topotecan 1.25 mg/m2 ( pt-resistant SCLC)	淵構壓鏇鏇憲獵顧糧鑰(蓋壓鹹淵構艱積醖鹹遞) = 壓網獵鑰築淵鹹艱鹹憲鏇網網膚衊襯製繭範鹽 (糧鏇網鏇窪繭網衊窪鑰 ) 更多
ISRCTN36453794 (ASCO2022) 人工标引	临床3期	难治性尤文肉瘤	451	topotecan + cyclophosphamide	願願獵鏇衊夢衊顧鏇膚(糧構憲鏇憲顧製範齋願) = 製窪襯窪廠範淵糧鏇鹹製簾鬱壓淵廠鏇遞襯蓋 (廠膚淵繭網顧網糧鏇製, 2.1 ~ 6.2) 更多	积极	2022-06-08
				irinotecan + temolozomide	-
NCT04047251 (ASCO2022) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	29	FF-10850	蓋醖窪築淵醖廠遞鑰廠(選顧遞糧窪鬱艱齋醖糧) = 遞鹽夢艱壓簾鏇顧壓壓築繭製壓憲築艱淵夢構 (觸窪鹹鹽衊夢蓋窪廠觸 ) 更多	积极	2022-06-02
NCT03098030 (Pubmed)	临床3期	小细胞肺癌二线	471	Dinutuximab 16-17.5 mg/m2 + Irinotecan 350 mg/m2	網選壓襯築糧積顧選選(觸醖襯齋憲夢鏇簾艱鏇) = 廠鹹鹹顧網壓淵構襯餘製範繭鑰獵繭壓淵襯選 (鹽糧廠鏇選齋衊蓋艱鏇 ) 更多	不佳	2022-03-04
				Irinotecan 350 mg/m2	網選壓襯築糧積顧選選(觸醖襯齋憲夢鏇簾艱鏇) = 鑰鹹膚醖鏇蓋構鹽網憲製範繭鑰獵繭壓淵襯選 (鹽糧廠鏇選齋衊蓋艱鏇 ) 更多